Beta-blockers as sub-optimal treatment for hypertension: time for first-line therapy revision?
Narkiewicz
Krzysztof
K
Kjeldsen
Sverre E
SE
Oparil
Suzanne
S
Hedner
Thomas
T
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000375:Aging / Q000502:physiology; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D004363:Drug Utilization; D005060:Europe; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001262:Atenolol